

**PENGANA HIGH CONVICTION EQUITIES FUND**
**DESCRIPTION**

The Pengana High Conviction Equities Fund (the Fund) invests globally in a concentrated portfolio of up to 20 stocks. The Fund can invest in both small and large cap stocks and is diversified across countries and sectors. We avoid investment in companies that are currently, in our opinion, unnecessarily harmful to people, animals or the environment.

**STATISTICAL DATA**
**VOLATILITY<sup>3</sup>** 25%


**NUMBER OF STOCKS** 19

**BETA<sup>4</sup>** 0.61

**MAXIMUM DRAW DOWN** -20.2%

**PERFORMANCE TABLE**
**NET PERFORMANCE FOR PERIODS ENDING 31 Mar 2022<sup>1</sup>**

	1 MTH	1 YEAR	2 YEARS P.A.	3 YEARS P.A.	5 YEARS P.A.	SINCE INCEPTION P.A.
High Conviction Equities Fund Class A	-8.0%	-15.3%	16.1%	8.2%	8.5%	25.4%
MSCI World Total Return Index (net, AUD)	-0.7%	11.7%	17.6%	12.9%	12.8%	11.8%
RBA Cash Rate plus 3%	0.3%	3.1%	3.1%	3.4%	3.8%	4.2%

**PERFORMANCE CHART**
**NET PERFORMANCE SINCE INCEPTION<sup>2</sup>**

**TOP HOLDINGS (ALPHABETICALLY)**

Ciena Corp	Information Technology
F45 Training Holdings Inc	Consumer Discretionary
Lamb Weston Holdings Inc	Consumer Staples
Renesas	Information Technology
Telix Pharmaceuticals Ltd	Health Care

**SECTOR BREAKDOWN**

Consumer Discretionary	27.1%
Consumer Staples	7%
Health Care	24.1%
Information Technology	27.7%
Real Estate	6%
Communication Services	4%
Cash	4.2%

**CAPITALISATION BREAKDOWN**

Under 5bn USD	46%
In between 5bn - 10bn USD	28.2%
In between 10bn - 100bn USD	21.7%
Cash	4.2%

**REGION BREAKDOWN**

North America	39%
Europe ex-UK	13.7%
Australia/New Zealand	21.8%
Japan	16.6%
UK	4.8%
Cash	4.2%

## RUSSIA'S INVASION OF UKRAINE CONTINUE TO ROIL MARKETS

### COMMENTARY


The fund fell 8% in March as the Russian invasion of Ukraine continue to roil markets.

March was a tough month for the strategy as some of our largest holdings were hard hit by the market, but it wasn't all bad news.

Australian radiotherapy producer **Telix** fell 15% after the FDA approved Novartis' radiotherapy drug Pluvicto for the treatment of prostate cancer. This approval was expected, however they also approved a companion diagnostic called Locametz which competes with Telix' lead product Illucix. This clearly disappointed the market as it was not expected until year end. We view the share price fall as an overreaction and took the opportunity to buy back the Telix shares which we sold at higher prices last year. We are not overly concerned by Novartis' entry into the prostate diagnostic market as Novartis sales force is very much focused on oncologists whereas Telix targets the larger urologist population. In addition, Telix' major distributors in the US have strong financial incentives to market and sell Telix' product and finally Telix has a pipeline of additional products which these distributors can sell in future which Novartis does not. Illucix, the company's first product, a diagnostic for prostate cancer with an addressable market of AUD\$1.5-\$2bn commenced selling in early April. We expect a rapid ramp of sales over coming quarters which we believe will drive the shares higher. The company has a market value of AUD\$1.4bn and \$200mln of cash. We expect AUD\$200mln-\$300mln in revenue in CY2023. A second product, a diagnostic for Renal cancer should be approved in 2023 and boost growth in 2024.

US listed gym franchise **F45** and Australian listed **Ardent Leisure** which owns US amusement centres were down 33% and 16% respectively on little news. We continue to like the companies as they share three powerful value creation drivers. First, both have well-funded new store openings (for F45 see the figure below). Secondly, there is strong demand for their products with F45 ranked tenth on website Entrepreneurs fastest growing franchises award (<https://www.entrepreneur.com/franchises/fastestgrowing>) whilst Ardent has experienced phenomenal like for like growth as the concept has been reinvigorated under new management. Thirdly, both demonstrate exceptional return on capital metrics, and growth potential yet trade at a discount to peers with lower growth and returns. These two stocks generated significant outperformance in February, but this reversed in March with share prices returning to around our entry point which we struggle to reconcile with peer outperformance over this period. F45 is trading on 10x 2023 PE with no debt which seems cheap relative to its growth profile.

**Fig 2 F45's open studio footprint by region at year-end**




On the brighter side, also on the basis of little news, the Norwegian bladder cancer diagnostic producer **Photocure** rose 14% although we expect strong upcoming results as cancer diagnostic procedures increase following the covid epidemic.


Australian immuno-oncology drug developer **Immutep** rose 11% after reporting a small study of late-stage lung cancer patients who had failed other treatments. The company will also release data on early-stage lung cancer patients at the world's largest cancer conference ASCO in the USA in June with abstracts released in late May. It continues enrolling its Phase 2b study in Head and Neck cancer which could be used to register Efti if the results are strong, where the company has fast track approval from the FDA with interim results expected later this year and final results in mid-2023. At the time of writing Immutep has a market value of \$300mln with cash of \$100mln which we think is highly attractive given deals for early-stage immunotherapy assets are generally in the USD2-5bn range.

FEATURES	
APIR CODE	HHA0020AU
REDEMPTION PRICE	A\$ 1.01
FEES *	Management Fee: 1.80% p.a. (Class A)   1.25% p.a. (Class B) Performance Fee: 15.38% (Class A)   20% (Class B)
MINIMUM INITIAL INVESTMENT	A\$10,000
FUM AT MONTH END	A\$ 39.99m
STRATEGY INCEPTION DATE	11 December 2014
BENCHMARK	RBA Cash Rate + 3%

### FUND MANAGERS



**James McDonald**  
Portfolio Manager



**Jeremy Bendeich**  
Portfolio Manager

1. Net performance figures are shown are those of Class A Units, after all fees and expenses and assume reinvestment of distributions. No allowance has been made for buy/sell spreads. Past performance is not a reliable indicator of future performance, the value of investments can go up and down.
  2. Inception 11 December 2014.
  3. Annualised standard deviation since inception.
  4. Relative to MSCI World. Using daily returns.
- \* For further information regarding fees please see the PDS available on our website.

## PENGANA HIGH CONVICTION EQUITIES FUND

### PENGANA CAPITAL LIMITED

ABN 30 103 800 568  
AFSL 226566

### CLIENT SERVICE

T: +61 2 8524 9900  
F: +61 2 8524 9901  
E: [clientservice@pengana.com](mailto:clientservice@pengana.com)



### PENGANA.COM

Pengana Capital Limited (ABN 30 103 800 568, AFSL 226566) ("Pengana") is the issuer of units in the Pengana High Conviction Equities Fund (ARSN 602 546 332) (the "Fund"). A product disclosure statement for the Fund is available and can be obtained from our distribution team or website. A person should obtain a copy of the product disclosure statement and should consider the product disclosure statement carefully before deciding whether to acquire, or to continue to hold, or making any other decision in respect of, the units in the Fund. This report was prepared by Pengana and does not contain any investment recommendation or investment advice. This report has been prepared without taking account of any person's objectives, financial situation or needs. Therefore, before acting on any information contained within this report a person should consider the appropriateness of the information, having regard to their objectives, financial situation and needs. Neither Pengana nor its related entities, directors or officers guarantees the performance of, or the repayment of capital or income invested in the Fund.